Researchers at Stanford have developed a new catalog of compact transcription effector domains and fused them onto DNA binding domains to engineer synthetic transcription factors.
Stanford researchers have identified a biomarker on cartilage precursor cells that can predict which cells will develop into inflammation-resistant and functionally appropriate tissue for autologous transplants to treat osteoarthritis.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??
Researchers in Prof. Karl Diesseroth's laboratory have discovered a Dopamine receptor type 2 specific promoter (D2SP) that can be used to transfect, identify and isolate Dopamine R2 (D2R)-expressing cells.
The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking.
Ion channel dysfunctions lead to a wide array of illnesses including epilepsy, cardiac arrhythmia and type II diabetes. However, the number of clinically approved drugs for restoring normal ion channel function is limited.
Researchers in Dr. Karl Deisseroth's laboratory have developed a novel method to rapidly identify neurophysiological measures associated with psychiatric disease and then use those correlates to screen for therapeutics.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
Researchers in Dr. Karl Deisseroth's laboratory at Stanford University have developed a novel suite of genetically-encodable, optically-activated modulators of second messengers (such as cAMP and IP3).